title: Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus.
abstract: Diabetes mellitus is a major risk factor for restenosis in patients undergoing percutaneous coronary intervention. Randomized controlled trials comparing drug-eluting stents (DESs) with bare metal stents (BMSs) showed a marked decrease in in-stent restenosis and target lesion revascularization with DESs in the total patient population enrolled in the studies, including patients with diabetes. However, it remains unclear whether the antirestenotic benefit of DESs is preserved in the high-risk diabetic subgroup. MEDLINE, EMBASE, ISI Web of Knowledge, Current Contents, International Pharmaceutical Abstracts, and recent Scientific Sessions databases were searched to identify relevant clinical trials comparing DESs with BMSs. A randomized controlled trial was included if it provided outcome data for patients with diabetes for > or =1 of the following: late lumen loss, in-stent restenosis, or target lesion revascularization. Data were combined using fixed-effects models, and standard tests for heterogeneity were performed. Eight studies with 1,520 patients with diabetes were identified that reported > or =1 outcome of interest. Mean late lumen losses (7 studies) were 0.93 mm (95% confidence interval [CI] 0.510 to 1.348) with BMSs and 0.18 mm (95% CI -0.088 to +0.446) with DESs. For patients receiving a DES, this translated into a marked decrease in in-stent restenosis (7 studies, RR 0.14, 95% CI 0.10 to 0.22, p <0.001) and target lesion revascularization (8 studies, RR 0.34, 95% CI 0.26 to 0.45, p <0.001). DES use is associated with a marked decrease in in-stent restenosis and target lesion revascularization in patients with diabetes. In conclusion, the analysis supports the current widespread use of DESs in these high-risk patients.
authors.affiliation: University Michigan Medical School, Ann Arbor VA Medical Center, Ann Arbor, Michigan, USA.
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Boyden
authors.forename: Brahmajee K
authors.initials: BK
authors.lastname: Nallamothu
authors.forename: Mauro
authors.initials: M
authors.lastname: Moscucci
authors.forename: Paul S
authors.initials: PS
authors.lastname: Chan
authors.forename: P Michael
authors.initials: PM
authors.lastname: Grossman
authors.forename: Thomas T
authors.initials: TT
authors.lastname: Tsai
authors.forename: Stanley J
authors.initials: SJ
authors.lastname: Chetcuti
authors.forename: Eric R
authors.initials: ER
authors.lastname: Bates
authors.forename: Hitinder S
authors.initials: HS
authors.lastname: Gurm
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D019917:Blood Vessel Prosthesis Implantation; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000150:complications / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control*; D016208:Databases, Factual; D048909:Diabetes Complications / Q000628:therapy*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005500:Follow-Up Studies; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use; D011474:Prosthesis Design; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000627:therapeutic use; D015607:Stents; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D017239:Paclitaxel; D020123:Sirolimus